Rx Target Found For HPV, Hep C And Related Cancers
The complex genetic programs controlling the function of cells and the organs, nerves, and tissues that they form are expressed through the concerted contributions of some 30,000 unique proteins that constitute the human genome. Coordination of these proteins is controlled by a small set of master regulators that sense the environment of the cell and alter subtle features of the genetic programs to maintain metabolic balance, called cellular homeostasis. More radical alterations in the genetic programs due to gene mutation or in response to viral or bacterial infection frequently lead to conditions that can result in cancer or developmental defects.
Lead investigator Dr. Virginia Ronchi, a postdoctoral fellow, and research associate Jennifer Klein, working in the laboratory of Dr. Arthur Haas, Professor and Head of Biochemistry and Molecular Biology at the LSU Health Sciences Center New Orleans School of Medicine, focused on the E6AP enzyme. This enzyme regulates the functions of several dozen different proteins involved in key homoeostatic processes. The E6AP protein belongs to a class of enzymes known as ubiquitin ligases. E6AP controls its target protein functions by attaching a smaller protein called ubiquitin to them that serves as a molecular flag to signal removal of the target by a large cellular nanomachine called the 26S proteasome.
Inherited mutations in the E6AP gene that block its activity result in Angelman's syndrome, a developmental condition characterized by severe mental retardation in children because the brain is unable to "learn" by adapting its nerve connections to outside stimuli. Other mutations that cause a duplication of the E6AP gene and increased activity are thought to cause some forms of inherited Autism Spectrum Disorder. In other tissues, the genetic program of the Human Papillomavirus produces an E6 viral protein following infection that hijacks the E6AP enzyme to target a different set of cells, not only ensuring the ability of the virus to replicate but causing uncontrolled growth resulting in benign skin tags, warts, or cervical cancer, depending on the site of infection. The Hepatitis C virus exploits a similar strategy to ensure its replication in the liver by expressing a different protein that redirects the function of E6AP, resulting in cirrhosis and liver cancer in the chronically infected.
The LSUHSC investigators used the ability of E6AP to form chains of ubiquitin as a window into the molecular function of the enzyme. The studies provide a description of the mechanism for the enzyme at the molecular level which provides potential strategies for designing drugs to block E6AP function in the case of the Human Papillomavirus and Hepatitis C virus. Because E6AP is similar to a larger family of related master regulators that control other cell functions, knowledge about it may also apply to future drug design for enzymes involved in many other diseases.
"The current work by Ronchi and Klein marks a major advance in our understanding of this important class of cell regulators and redefines more than 15 years of work in the field by other investigators," notes Dr. Haas.
The research was supported by a grant from the National Institutes of Health.
Louisiana State University Health Sciences Center
Source: EurekAlert!, the online, global news service operated by AAAS, the science society
Please use one of the following formats to cite this article in your essay, paper or report:
Louisiana State University Health Sciences Center. "Rx Target Found For HPV, Hep C And Related Cancers." Medical News Today. MediLexicon, Intl., 15 Apr. 2013. Web.
24 Feb. 2017. <http://www.medicalnewstoday.com/releases/258969.php>
Louisiana State University Health Sciences Center. (2013, April 15). "Rx Target Found For HPV, Hep C And Related Cancers." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.